Department of Medical Biotechnologies, Section of Cardiology, University of Siena, 53100 Siena, Italy.
Biomolecules. 2022 Feb 19;12(2):334. doi: 10.3390/biom12020334.
Left ventricular assist devices (LVADs) have been representing a cornerstone therapy for patients with end-stage heart failure during the last decades. However, their use induces several pathophysiological modifications which are partially responsible for the complications that typically characterize these patients, such as right ventricular failure, thromboembolic events, as well as bleedings. During the last years, biomarkers involved in the pathways of neurohormonal activation, myocardial injury, adverse remodeling, oxidative stress and systemic inflammation have raised attention. The search and analysis of potential biomarkers in LVAD patients could lead to the identification of a subset of patients with an increased risk of developing these adverse events. This could then promote a closer follow-up as well as therapeutic modifications. Furthermore, it might highlight some new therapeutic pharmacological targets that could lead to improved long-term survival. The aim of this review is to provide current evidence on the role of different biomarkers in patients with LVAD, in particular highlighting their possible implications in clinical practice.
在过去的几十年中，左心室辅助装置（LVAD）一直是治疗终末期心力衰竭患者的基石疗法。然而，它们的使用会引起多种病理生理改变，这些改变部分是导致这些患者出现典型并发症的原因，如右心衰竭、血栓栓塞事件以及出血。近年来，神经激素激活途径、心肌损伤、不良重构、氧化应激和全身炎症中的生物标志物引起了人们的关注。在 LVAD 患者中寻找和分析潜在的生物标志物，可能有助于确定发生这些不良事件风险增加的患者亚群。这可以促进更密切的随访和治疗调整。此外，它可能突出一些新的治疗药理学靶点，从而提高长期生存率。本文综述的目的是提供目前关于 LVAD 患者不同生物标志物作用的证据，特别是强调它们在临床实践中的可能意义。
